Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis B

LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) --  (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the formation of a Scientific Advisory Board (SAB) for one of its promising pipelines. Effective immediately, the Hepatitis B Virus (HBV) Cure SAB will include:

• Carol Brosgart, MD, Chairperson of the SAB and member of the Enochian BioSciences Board of Directors and Clinical Professor of Medicine, Biostatistics and Epidemiology, University of California, San Francisco (UCSF) ;
• Peter Revill, PhD, Senior Medical Scientist, Victorian Diseases Reference Laboratory, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; and
• Fabien Zoulim, MD, PhD, Clinical Professor of Medicine at Lyon University; Medical Director, Hepatology Department, Hospices Civils de Lyon; and Scientific Director, Department of Immunology and Virology, INSERM Unit 1052, France.

Chronic HBV liver disease affects approximately 257 million people globally and kills nearly one million people every year. Enochian BioSciences, in partnership with Seraph Research Institute, recently presented data on the scientific progress of its potential HBV cure product at the annual meeting of the American Society of Gene and Cell Therapy (https://www.enochianbio.com/enochian-biosciences-announces-three-scien ...). The newly formed HBV SAB will provide counsel to help accelerate the development of a potential treatment or cure.

Dr. Brosgart joined the Board of Directors of Enochian BioSciences in January, 2020. She is a leader in HBV, HIV and infectious diseases science and industry
(https://www.enochianbio.com/enochian-biosciences-a-company-focused-on- ...).

Dr. Revill and Dr. Zoulim are internationally recognized leaders in HBV cure and treatment research. Dr. Zoulim has published more than 400 peer-reviewed papers, and heads the HBV Cure Task Force of ANRS, the French National Agency for Research on AIDS and Hepatitis, and an autonomous agency within INSERM. INSERM is a government funded agency aiming at improving health through progress in the knowledge of diseases, treatment innovation and public health research. INSERM supports research from bench to bedside and develops its research strategy thanks to partnership with health authorities as well as public and private stakeholders.